Assessment of Response to Regorafenib in Patients with Glioma Relapse Using 18 F-FET PET and MRI
Journal of Nuclear Medicine · 2026-03 · 67 (3) · 366-373
DOI: 10.2967/jnumed.125.270946 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.01.2026. Verfasst von Jan-Michael Werner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Phenylurea Compounds, Positron-Emission Tomography, Pyridines, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Neuroimaging markers predicting response to regorafenib in patients with glioma relapse remain scarce; we evaluated whether early changes in amino acid PET and MRI are associated with overall survival (OS).
Methods
Twenty adult patients with central nervous system World Health Organization grade 3 or 4 gliomas at relapse (glioblastoma, 85%) were treated according to the REGOMA trial. Amino acid PET using the tracer O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) and MRI were performed at baseline and after 2 cycles. From these imaging data, tumor-to-brain ratios (TBR), metabolic tumor volumes, the dynamic parameters (time to peak and slope), and apparent diffusion coefficients were obtained. Parameter thresholds to predict an OS of 6 mo or longer as a surrogate for response were defined using receiver operating characteristic curve analyses. In addition, Response Assessment in Neuro-Oncology criteria for MRI and PET were used to evaluate response. The association of imaging parameters with OS was evaluated using univariate and multivariate survival estimates.
Results
Patients received a median of 3 regorafenib cycles (range, 2-16 cycles). The median follow-up was 10.3 mo (range, 3.2-27.6 mo). A decline in mean TBR values by 10% or greater was significantly associated with longer OS (10.4 vs. 5.3 mo; P = 0.027). Other 18F-FET PET parameters, Response Assessment in Neuro-Oncology criteria for MRI and PET, and apparent diffusion coefficient values were not associated with OS (P > 0.05). At follow-up, a mean TBR of 2.0 or less was associated with longer OS (10.6 vs. 4.5 mo; P = 0.009). Multivariate survival analyses revealed that changes in mean TBR values were independently associated with longer OS (P = 0.006; hazard ratio, 0.200), and a lower mean TBR at follow-up was strongly prognostic (P < 0.001; hazard ratio, 0.030).
Conclusion
18F-FET PET parameters are clinically valuable for identifying responders to regorafenib early after treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
- Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
- Institute of Radiology, Division of Neuroradiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
- Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Zitieren
APA
Werner, J. M., Lohmann, P., Kabbasch, C., Wollring, M. M., Tscherpel, C., Goertz, L., Rosen, J., Stoffels, G., Goldbrunner, R., Mottaghy, F. M., Langen, K. J., Fink, G. R., & Galldiks, N. (2026). Assessment of Response to Regorafenib in Patients with Glioma Relapse Using 18 F-FET PET and MRI. Journal of Nuclear Medicine, 67(3), 366-373. https://doi.org/10.2967/jnumed.125.270946
Vancouver
Werner JM, Lohmann P, Kabbasch C, Wollring MM, Tscherpel C, Goertz L, et al. Assessment of Response to Regorafenib in Patients with Glioma Relapse Using 18 F-FET PET and MRI. Journal of Nuclear Medicine. 2026;67(3):366-373. doi:10.2967/jnumed.125.270946
BibTeX
@article{Werner2026,
author = {Werner, Jan-Michael and Lohmann, Philipp and Kabbasch, Christoph and Wollring, Michael M and Tscherpel, Caroline and Goertz, Lukas and Rosen, Jurij and Stoffels, Gabriele and Goldbrunner, Roland and Mottaghy, Felix M and Langen, Karl-Josef and Fink, Gereon R and Galldiks, Norbert},
title = {Assessment of Response to Regorafenib in Patients with Glioma Relapse Using 18 F-FET PET and MRI},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {3},
pages = {366--373},
doi = {10.2967/jnumed.125.270946}
}
EUVIMED